This record is sourced from an Exhibit 99.1 press release furnished with Solventum's Form 8-K filed September 2, 2025, announcing the completed closing of the divestiture (not merely its signing).
Three financial advisors jointly represented Solventum, the seller: Morgan Stanley & Co. LLC, Perella Weinberg Partners and J.P. Morgan Securities LLC, per the release's statement that "Morgan Stanley & Co. LLC, Perella Weinberg Partners and J.P. Morgan Securities LLC served as financial advisors to Solventum, and Cleary Gottlieb Steen & Hamilton served as legal advisor to Solventum." No financial advisor to Thermo Fisher is named in this release, and no single advisor among the three is designated as lead.
On the legal side, Cleary Gottlieb Steen & Hamilton represented Solventum; no legal advisor for Thermo Fisher is disclosed in this release.
In connection with the closing, Solventum updated its full-year 2025 guidance to reflect partial-year accretion from the divestiture, raising its adjusted EPS range to $5.88-$6.03 from a prior $5.80-$5.95, while leaving organic sales growth and free cash flow guidance unchanged; the company also noted it will provide transitional services and perform certain manufacturing and distribution activities for Thermo Fisher going forward.
Not disclosed in the sourced document is any EBITDA or revenue multiple implied by the $4.0 billion price, the identity of Thermo Fisher's financial or legal advisors, or the original signing date of the transaction (only the completed-closing date of September 2, 2025 is given).